Extended release formulation and method of treating adrenergic dysregulation

An oral dosage form comprising:

• (a) clonidine or a pharmaceutically acceptable salt thereof in an amount between about 0.001 wt % and 0.5 wt % of the oral dosage form;
• (b) a pharmaceutically acceptable hydrophilic matrix comprising,
• (i) at least one hydroxypropyl methylcellulose ether in an amount between 20 wt % and 80 wt % of the oral dosage form;
• (ii) at least one of starch, lactose, or dextrose in an amount between 20 wt % and 80 wt % of the oral dosage form;
• and
• (iii) a metal alkyl sulfate;
• and
• (c) optionally a metal stearate and/or colloidal silica.

An oral dosage form consisting essentially of:

• (a) clonidine hydrochloride in an amount between about 0.001 wt % and 0.5 wt % of the oral dosage form;
• (b) a pharmaceutically acceptable hydrophilic matrix comprising,
• (i) at least one hydroxypropyl methylcellulose ether in an amount between 30 wt % and 50 wt % of the oral dosage form;
• (ii) at least one of starch, lactose, or dextrose in an amount between 50 wt % and 70 wt % of the oral dosage form;
• and
• (iii) a metal alkyl sulfate in an amount of between about 2 wt % and about 6 wt % of the oral dosage form;
• and
• (c) a metal stearate and/or colloidal silica.